-
Join us Thursday, Dec. 7, at 2 p.m. ET for the next Research Journal Club with Tammuella Chrisentery-Singleton, MD, the chief science officer at the American Thrombosis and Hemostasis Network. She will discuss a recent study published in Haemophilia on rare blood disorders, and the long-term follow-up of patients with congenital thrombotic thrombocytopenia purpura, receiving a plasma-derived factor VIII that contains ADAMTS13.
Link to the article: http://dx.doi.org/10.1111/hae.14891
Link to ATHN’s website: https://athn.org/
Chrisentery-Singleton is board-certified in general pediatrics and pediatric hematology/oncology. Her areas of special interest include sickle cell disease, rare blood disorders, gene therapy, and musculoskeletal ultrasound in hemophilia patients. She has authored numerous publications and led more than 60 clinical trials and research studies—including serving as the principal investigator for ATHN 16: Safety of SEVENFACT® for the Treatment of Bleeding Events in Patients with Hemophilia A or B with Inhibitor.